论文部分内容阅读
作者对117例中数年龄43岁(15～60岁)的AML患者在首次诱导缓解后进行自体和同种异基因骨髓移植。骨髓移植(BMT)前88例行DNR、Ara-C化疗1～2个疗程,29例行6-TG、Ara-C和DNR化疗,获完全缓解(CR)后在中数时间3.8或3.0个月进行自体或同种异基因BMT。自体BMT在移植前4和3天,分别应用CTX60mg/kg体重,静脉注射。移植前1天进行全身照射(8GY,机体正中并部分肺遮蔽)(TBI),于TBI后第二天给予自体骨髓输注,BMT后不给予抗白血病治疗。同时异基因BMT由HLA匹配的同胞供髓。10例于BMT前进行
The authors of 117 patients aged 43 years (15 to 60 years old) AML patients with autologous and allogeneic bone marrow transplantation after the first induction of remission. Eighty-eight patients underwent BMT with DNR and Ara-C chemotherapy for 1 to 2 courses of chemotherapy and 29 patients for 6-TG, Ara-C and DNR chemotherapy before BMT. After complete remission (CR), they were 3.8 or 3.0 Month for autologous or allogeneic BMT. Autologous BMT was intravenously injected with CTX 60 mg / kg body weight 4 and 3 days prior to transplantation, respectively. Whole body irradiation (8GY, median and partial lung obstruction) (TBI) was performed one day prior to transplantation, autologous bone marrow infusion was given on the second day after TBI, and anti-leukemia treatment was not given after BMT. At the same time allogeneic BMT by HLA matching siblings for the marrow. Ten cases were performed before BMT